Literature DB >> 30887733

Postendoscopic retrograde cholangiopancreatography pancreatitis.

Hsiang-Yao Shih1, Wen-Hung Hsu1,2, Chao-Hung Kuo2,3.   

Abstract

Endoscopic retrograde cholangiopancreatography (ERCP) has been a mainstay examination to clarify the biliary and pancreatic system. Not just diagnostic purpose, it could achieve therapeutic goal. Under the trend of more and more procedures about ERCP being interventional, the rate of adverse events after the procedure is increasing. Among them, post-ERCP pancreatitis (PEP) is the most common and sometimes tremendous complication. This mini-review will overview the PEP from definition, pathogenesis, and risk factors to prevention.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  endoscopic retrograde cholangiopancreatography; pancreatitis; postendoscopic retrograde cholangiopancreatography pancreatitis

Mesh:

Year:  2019        PMID: 30887733     DOI: 10.1002/kjm2.12040

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  3 in total

1.  Serum lipase as a biomarker for early prediction and diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Yu Zhang; Xiaoling Ye; Xinyue Wan; Tao Deng
Journal:  Ir J Med Sci       Date:  2019-08-28       Impact factor: 1.568

2.  Endoscopic retrograde cholangiopancreatography in children with symptomatic pancreaticobiliary maljunction: A retrospective multicenter study.

Authors:  Jing-Qing Zeng; Zhao-Hui Deng; Kai-Hua Yang; Tian-Ao Zhang; Wen-Yu Wang; Jian-Mei Ji; Ya-Bin Hu; Chun-Di Xu; Biao Gong
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

Review 3.  Application of imaging techniques in pancreaticobiliary maljunction.

Authors:  Jin-Ye Wang; Pei-Yuan Mu; Ye-Kai Xu; Yuan-Yuan Bai; Dong-Hua Shen
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.